- ticket title
- Repeat concussions declining in U.S. high school sports
- Three drug distributors in talks to settle opioid litigation for $18 billion – WSJ
- Weight-loss surgery tied to lower risk of birth defects
- Missouri appeals court overturns $110 million Johnson & Johnson talc verdict
- Michigan judge blocks flavored vape ban as Juul faces wrongful death lawsuit
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann/File Photo
ZURICH (Reuters) – Swiss drugmaker Roche on Tuesday won approval in Japan for Rozlytrek as the world’s biggest maker of cancer drugs pushes ahead in personalized medicines that require a biomarker test to identify prospective patients.
Roche said Japan is the first country to approve Rozlytrek, also known as entrectinib, targeting people with NTRK fusion-positive solid tumors, across 10 different tumor types, including those with central nervous system metastases.
Reporting by John Miller; Editing by Michelle Martin